The Claim
In individuals without cardiovascular disease at intermediate risk, the combination of rosuvastatin (10 mg), candesartan (16 mg), and hydrochlorothiazide (12.5 mg) increases the incidence of muscle weakness and dizziness compared to placebo, but does not lead to higher rates of treatment discontinuation.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people without heart disease but at intermediate risk, taking a combination of rosuvastatin, candesartan, and hydrochlorothiazide causes more muscle weakness and dizziness than taking a placebo, but does not cause more people to stop taking the medication.
See the scientific wording
In individuals without cardiovascular disease at intermediate risk, the combination of rosuvastatin (10 mg), candesartan (16 mg), and hydrochlorothiazide (12.5 mg) increases the incidence of muscle weakness and dizziness compared to placebo, but does not lead to higher rates of treatment discontinuation.
The medicine reduces sodium and fluid in the body, which lowers potassium levels and makes muscle cells less able to generate energy. This causes muscles to feel weak and the brain to receive less blood flow, leading to dizziness.
What the research says
1 studyStudy: Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.
People taking a pill with three medicines felt more muscle weakness and dizziness than those taking dummy pills, but they didn’t quit taking their medicine any more often — just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.